FDA-Approved MedicationUpdated November 2026

Zepbound Guide

Zepbound is the brand-name formulation of tirzepatide 2.5–15mg specifically FDA-approved for chronic weight management, launched by Eli Lilly in late 2023. It is chemically identical to Mounjaro but approved specifically for obesity treatment, making it eligible for different insurance coverage pathways and savings programs.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed

At a Glance

Generic NameTirzepatide
Brand NamesZepbound
FDA StatusFDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity (November 2023), and to treat moderate-to-severe obstructive sleep apnea in adults with obesity[1]
Approval DateNovember 8, 2023[1]

How Zepbound Works

Zepbound works through tirzepatide's dual GIP/GLP-1 mechanism to reduce appetite through both central brain signals and peripheral metabolic effects. GLP-1 activation creates feelings of fullness and slows digestion; GIP activation may additionally enhance fat metabolism and energy expenditure. This twin-hormone approach produces more weight loss than any single-pathway agent.[2]

Dosing Schedule

Zepbound uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].

Weeks 1–42.5mg/week
Weeks 5–85mg/week
Weeks 9–127.5mg/week
Weeks 13–1610mg/week
Weeks 17–2012.5mg/week
Week 21+Maintenance 5, 10, or 15mg/week (15mg max)

Side Effects

Common: nausea (25–29%), diarrhea (19–23%), vomiting (8–13%), constipation (11–17%), abdominal pain (9–10%) across the 5, 10, and 15 mg doses, injection site redness. Nausea is most common during dose escalation and typically resolves within a month of each new dose. Serious (rare): pancreatitis, cholelithiasis (gallstones), thyroid tumor risk noted in animal models.[1][2]

This is not a complete list. Consult your healthcare provider or prescriber for full safety information. The complete adverse reaction profile is published in the current FDA prescribing information[1].

Clinical Trial Results

In the SURMOUNT-1 trial, Zepbound (tirzepatide 15mg) produced an average weight loss of 22.5% (about 52 lbs) over 72 weeks — the highest of any anti-obesity medication ever studied. At 10mg, participants lost 21.4%; at 5mg, they lost 15.0%. 91% of participants lost at least 5% of body weight at the 15mg dose.[2][3]

Source: Published clinical trial data (STEP / SURMOUNT trial series) — see the Sources panel below for full citations.

Where to Get Zepbound

These telehealth providers offer access to tirzepatide with online consultations and home delivery. Before you book a consult, our guide to getting Zepbound online walks through eligibility, the prescriber visit, and what legitimate pharmacy fulfillment looks like.

8.3/ 10
Partner

Found

Best for: medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help

★★★★☆4.2/5

Editorial score · methodology

$289/4 wkssemaglutide
billed per 4 weeks
$359/4 wkstirzepatide
billed per 4 weeks
CompoundedSemaglutideTirzepatideOrforglipron
Get StartedRead full Found review →
8.1/ 10
Partner

RxSpan MD

Best for: physician-led, pharmacy-transparent compounded GLP-1 with brand-name options

★★★★☆4.1/5

Editorial score · methodology

$249/mosemaglutide
$329/motirzepatide
CompoundedSemaglutideTirzepatideGHK-CuGlutathioneLegitScript Verified
Get StartedRead full RxSpan MD review →
8.0/ 10
Partner

Sesame Care

Best for: Brand-name GLP-1s at cash prices, no compounding

★★★★☆4/5

Editorial score · methodology

$149/mosemaglutide
see plan details
BrandSemaglutideTirzepatideOrforglipron
Get StartedRead full Sesame Care review →
8.0/ 10
Partner

ShedRx

Best for: compounded GLP-1 as an injection, drops or lozenges, with lower rates on 6- and 12-month plans

★★★★☆4/5

Editorial score · methodology

$199/mosemaglutide
plan-length pricing
$279/motirzepatide
“starting at” price
CompoundedSemaglutideTirzepatideOrforglipronGHK-Cu
Get StartedRead full ShedRx review →
7.9/ 10
Partner

GobyMeds

Best for: no-membership, no-auto-renew compounded GLP-1 orders, from about $99/mo on a 3-month bundle

★★★★☆4/5

Editorial score · methodology

$169/mosemaglutide
“starting at” price
$299/motirzepatide
“starting at” price
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full GobyMeds review →
7.7/ 10
Partner

Ro

Best for: FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help

★★★★☆3.9/5

Editorial score · methodology

$149/mosemaglutide
+ required membership
BrandSemaglutideTirzepatideOrforglipron
Get StartedRead full Ro review →

Each provider's lowest ongoing monthly cash price for Zepbound, sorted cheapest first (no copays, membership fees or intro offers). Both compounded and brand-name prescriptions are generally FSA/HSA eligible under IRS Publication 502[6]. Prices may vary based on dose.

ProviderFrom (ongoing)
Amazon One Medical$299/moper 4 weeksVisit
Found$299/mostarting doseVisit
GoodRx$299/morises with doseVisit
Heally$299/mostarting doseVisit
Healthspan$299/mo+ required membershipVisit
Hers$299/mo+ required membershipVisit
Hims$299/mo+ required membershipVisit
HuHealth$299/mosee plan detailsVisit
Imbue Health$299/mo+ required membershipVisit
Knownwell$299/mosee plan detailsVisit
LifeMD$299/mo+ required membershipVisit
Measured$299/mo+ required membershipVisit
Médetone$299/mo+ required membershipVisit
Ro$299/mo+ required membershipVisit
Sesame Care$299/mosee plan detailsVisit
ShedRx$299/mo+ required membershipVisit
Temi$299/morises with doseVisit
Aspire Health$348/moper 4 weeksVisit
PreventiveMD$348/mo“starting at” priceVisit
Mochi Health$378/mo+ added feeVisit
GOAL.MD$394/mosee plan detailsVisit
Alloy$398/mostarting doseVisit
Tuyo Health$399/mo+ required membershipVisit
Phoenix NP$403/moper 4 weeksVisit
Navio MD$445/morises with doseVisit
Maximus$450/mostarting doseVisit
AgelessRx$514/moafter intro offerVisit
WePeptideRx$699/moper 4 weeksVisit
Pallas Health$1,069/moper 4 weeksVisit
RxSpan MD$1,069/moVisit
altRX$1,249/moVisit
DudeMeds$1,350/mo3-month plan rateVisit
HeliMeds$1,396/moper 4 weeksVisit
Aquivia Health$1,399/mosee plan detailsVisit
GobyMeds$1,399/moVisit
Luvo Health$1,399/moper 4 weeksVisit
Meant$1,399/moentry-tier priceVisit
Medsol RX$1,399/mosee plan detailsVisit
Tomorrow$1,399/moVisit
Tryozi$1,399/moVisit
Vytora Health$1,399/moVisit
Effecty$1,400/mosee plan detailsVisit
SkinnyRx$1,400/mosee plan detailsVisit
Bon Health$1,469/mo+ added feeVisit
OrderlyMeds$1,498/mosee plan detailsVisit
BiltRx$1,499/mo+ consult feeVisit
Corsica Health$1,499/mosee plan detailsVisit
Livbetr$1,599/moVisit
Good Girl Rx$1,688/moVisit
Fridays$1,828/moVisit
NuuVim$1,892/mostarting doseVisit

Short-form verdict pages comparing Zepbound to other GLP-1 options with trial-anchored data, FDA-label dosing, and current manufacturer pricing.

See all drug-vs-drug verdicts, or compare every weight loss medication we cover.

Endpoint-by-endpoint breakdowns of the trials that shaped the Zepbound label, with primary-source numbers and FAQs.

SURMOUNT-1
SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) to once-weekly tirzepatide 5 mg, 10 mg, 15 mg, or placebo for 72 weeks. The 15-mg arm lost a mean 20.9% of body weight on the treatment-regimen estimand (NEJM publication) vs 3.1% with placebo; 91% achieved at least 5% loss and 57% achieved at least 20% loss. Every prespecified cardiometabolic measure — waist, systolic blood pressure, fasting insulin, triglycerides, HbA1c — improved. GI adverse events were dose-dependent and discontinuations for AEs ran 4.3-7.1% on tirzepatide vs 2.6% on placebo.
3 · N=2,539 · Last verified November 2026
SURMOUNT-OSA
SURMOUNT-OSA is the pair of phase-3 trials that drove the December 2024 FDA approval of Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity — the first drug ever approved for the condition. Eli Lilly ran two parallel master-protocol cohorts and reported them as one paper (Malhotra 2024 NEJM, PMID 38912654): SURMOUNT-OSA-1 (n=234) randomized adults not using positive airway pressure (PAP) therapy, and SURMOUNT-OSA-2 (n=235) randomized adults already established on PAP. After 52 weeks of weekly tirzepatide at maximum tolerated dose (10 or 15 mg), the apnea-hypopnea index dropped by 25.3 events/hour in cohort 1 (placebo-subtracted −20.0) and 29.3 events/hour in cohort 2 (placebo-subtracted −23.8). Body weight fell about 18-20%, hsCRP fell 1.4 mg/L in both cohorts, and systolic blood pressure fell 7.6-9.5 mmHg.
Phase 3 · N=469 · Last verified November 2026
SURMOUNT-2
SURMOUNT-2 randomized 938 adults with obesity and type 2 diabetes to once-weekly tirzepatide 10 mg, 15 mg, or placebo for 72 weeks. The 15-mg arm lost a mean 14.7% of body weight on the treatment-regimen estimand versus 3.2% with placebo, and dropped HbA1c by 2.22 percentage points from a mean baseline of 8.02%. On the efficacy estimand, nearly 87% of 15-mg participants reached at least 5% weight loss and 52% reached 15%, while 91% hit an HbA1c below 7%. The trial answered the question SURMOUNT-1 left open — does tirzepatide work for weight loss when diabetes is on board? — and underpinned Zepbound's positioning for the obesity-plus-T2D population.
3 · N=938 · Last verified November 2026
SURMOUNT-3
SURMOUNT-3 asked the question every patient and payer wants answered: does tirzepatide still work after someone has already lost weight on lifestyle alone? Eli Lilly enrolled 806 adults with obesity into a 12-week intensive lifestyle intervention, kept the 579 who lost at least 5% of their weight, and randomized them 1:1 to tirzepatide (titrated to max-tolerated 10 mg or 15 mg) or placebo for 72 more weeks of treatment, both groups continuing the lifestyle program. From the randomization point, tirzepatide drove an additional 18.4% mean weight loss versus a 2.5% regain on placebo — a placebo-subtracted 20.8 percentage points. Total weight loss across the lead-in and randomized phases reached roughly 26% on tirzepatide. The trial directly parallels STEP-3 (semaglutide plus intensive behavioral therapy) and is the strongest evidence against the argument that GLP-1 medications only work for people who have not yet tried lifestyle changes.
3 · N=579 · Last verified November 2026

Real patient questions about Zepbound pulled from named subreddits and answered with peer-reviewed trial data.

Scannable cheat sheets for dose schedules, missed-dose rules, and red-flag side effects — every number verified against the DailyMed FDA label.

Curated lists of the highest-impact peer-reviewed studies on Zepbound and related GLP-1 drugs. Every PMID is checked against its PubMed record.

Top 10 PubMed Studies on Tirzepatide for Weight Loss (2026)
Ten peer-reviewed tirzepatide weight-loss studies anchored to the SURMOUNT program (SURMOUNT-1 through SURMOUNT-5, plus SURMOUNT-CN and SURMOUNT-OSA), the SYNERGY-NASH liver-fibrosis trial, the SUMMIT HFpEF trial, and the SURPASS-2 head-to-head against semaglutide. Each entry includes the PMID, trial design, primary endpoint, and editorial summary.
10 ranked papers · Last verified November 2026
Top 10 PubMed Studies on Retatrutide (Triple Agonist GLP-1/GIP/Glucagon) 2026
Ten peer-reviewed retatrutide studies on Eli Lilly's triple GIP/GLP-1/glucagon receptor agonist. Three are phase 3 trials now in print: TRIUMPH-1 in obesity (Jastreboff, NEJM 2026), TRIUMPH-2 in obesity with type 2 diabetes (Bellido, Lancet 2026) and TRANSCEND-T2D-1 in type 2 diabetes (Bajaj, Lancet 2026). The rest trace the phase 2 obesity (Jastreboff 2023) and T2D (Rosenstock 2023) trials, the liver-fat substudy (Sanyal 2024), body composition (Coskun 2025), kidney parameters (Heerspink 2025), the TRANSCEND-CKD mechanistic kidney trial design (Heerspink 2026) and the molecular discovery paper (Coskun 2022). Each entry includes the PMID, trial design, primary endpoint and editorial summary.
10 ranked papers · Last verified November 2026
Top PubMed Studies on GLP-1 Drugs for Obstructive Sleep Apnea (2026)
Ten peer-reviewed studies that built the case for GLP-1-class drugs in obstructive sleep apnea (OSA). SURMOUNT-OSA (Malhotra 2024 NEJM) drove the December 2024 FDA approval of Zepbound for OSA, the first medication of any class with an OSA indication, and its 2026 Nature Medicine secondary analysis added cardiometabolic outcomes. The 2026 NEJM TRIUMPH-OSA trials of investigational retatrutide are the second phase 3 dataset. The list also covers the SCALE Sleep Apnea liraglutide trial, the Sleep AHEAD intensive-lifestyle trial and its 4-year follow-up, a CPAP-vs-liraglutide proof-of-concept RCT, the Wang/Schwab tongue-fat mechanism paper, STEP-HFpEF as adjacent context for OSA-overlap populations, and a 2025 meta-analysis. Each entry includes PMID, NCT, primary endpoint, and editorial summary.
10 ranked papers · Last verified November 2026
Top PubMed Studies on GLP-1 Drugs and Muscle / Lean Mass Loss (2026)
Ten peer-reviewed studies that frame the muscle-loss question on GLP-1 therapy. Most randomized data comes from DEXA substudies of obesity trials — SURMOUNT-1 (Look 2025 Diabetes Obes Metab), the retatrutide phase-2 T2D body-composition substudy (Coskun 2025 Lancet D&E), plus earlier liraglutide and semaglutide DXA work, which together show roughly 25-40% of weight lost on a GLP-1 is lean mass, comparable to or slightly worse than diet/exercise weight loss. The list also covers the Lundgren 2021 NEJM liraglutide-plus-exercise RCT, the Locatelli 2024 Diabetes Care resistance-exercise review, the Karakasis 2025 network meta-analysis, the Neeland 2024 mitigation-strategies review, the Jensen 2024 post-treatment follow-up of the Lundgren trial, the Linge 2024 Circulation muscle-mass adaptive-vs-maladaptive paper, the 2026 BELIEVE trial of bimagrumab plus semaglutide, and the Nunn 2024 activin-receptor antibody preclinical paper behind it. Each entry includes PMID, journal, primary endpoint where applicable, and editorial summary.
10 ranked papers · Last verified November 2026

Deep-dive articles from our research desk with primary-source trial data, FDA label verification, and editorial analysis.

Best Compounding Pharmacy for Tirzepatide? How to Choose a Legit One (2026)
There's no single best compounding pharmacy for tirzepatide — there's a checklist. 503A vs 503B, PCAB accreditation, state licensure, NABP/LegitScript, and a real prescriber. Plus the 2026 legal reality and our vetted providers.
9 min read6 citations
Switching From Semaglutide to Tirzepatide: Washout, Dose & What to Expect (2026)
Switching from semaglutide to tirzepatide: the short 3-7 day timing gap, why you restart at 2.5 mg (no dose-matching, no conversion chart), and what to expect. Prescriber-led.
9 min read6 citations
Mounjaro and Acid Reflux: Heartburn, GERD & How to Manage It (2026)
Is acid reflux a Mounjaro side effect? GERD, dyspepsia, and eructation are labeled tirzepatide reactions because it slows gastric emptying. Why heartburn and the 'Mounjaro burps' happen, how to manage them, the red flags, and why long-term weight loss usually improves reflux.
9 min read5 citations
How to Get Saxenda Online (2026): The Daily Liraglutide Pathways & Cost
Saxenda is daily liraglutide 3 mg — the original weight-loss GLP-1. How to get it online in 2026: legitimate telehealth pathways, cost by pathway, Saxenda vs the weekly GLP-1s (Wegovy/Zepbound), and safety.
9 min read4 citations
Zepbound & Mounjaro (Tirzepatide) Results Timeline: What to Expect Week by Week & Month by Month (2026)
What to expect on Zepbound and Mounjaro (tirzepatide) week by week and month by month. SURMOUNT-1 averaged ~15.0% / ~19.5% / ~20.9% body-weight loss at 5/10/15 mg by week 72 — a trial average, not a guarantee. An honest, prescriber-directed 2026 timeline.
11 min read6 citations
Does Inositol Help With Weight Loss in PCOS? Honest Evidence Review
Inositol's strongest evidence is for PCOS-related insulin resistance + ovulation (1-3 kg weight loss + restored cycles). For non-PCOS adults, inositol produces minimal weight effects.
19 min read15 citations

Frequently Asked Questions

FDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity (November 2023), and to treat moderate-to-severe obstructive sleep apnea in adults with obesity
Among the 51 providers in the cost comparison table above, Zepbound's lowest ongoing monthly cash price is $299 and the highest is $1,892, depending on provider, form and dose. These are medication prices only — copays, membership fees and intro offers are excluded. Always check for manufacturer savings programs.
Common: nausea (25–29%), diarrhea (19–23%), vomiting (8–13%), constipation (11–17%), abdominal pain (9–10%) across the 5, 10, and 15 mg doses, injection site redness. Nausea is most common during dose escalation and typically resolves within a month of each new dose. Serious (rare): pancreatitis, cholelithiasis (gallstones), thyroid tumor risk noted in animal models.
Zepbound requires a prescription from a licensed healthcare provider. You can get it through your primary care doctor, endocrinologist, or a telehealth platform. The telehealth providers listed above prescribe it online.
Sources & methodology (as of November 2026)
  1. 1.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  2. 2.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  3. 3.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
  4. 4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  5. 5.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  6. 6.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.